It is also being investigated in combination with palbociclib and fulvestrant in PIK3CA-mutated HR-positive, HER2-negative metastatic breast cancer in INAVO120 trial (NCT04191499) as well as in combination with fulvestrant compared to alpelisib plus fulvestrant in HR-positive, HER2-negative PIK3CA-mutated advanced breast cancers (NCT05646862). Here, PIK3CA is linked to breast carcinoma.